DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Given Consensus Recommendation of “Hold” by Brokerages

Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) have been assigned a consensus recommendation of “Hold” from the fifteen research firms that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $14.4167.

XRAY has been the topic of a number of recent analyst reports. Zacks Research upgraded DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. Barrington Research raised their target price on DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a research note on Monday, March 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of DENTSPLY SIRONA in a research report on Wednesday, January 21st. Barclays started coverage on DENTSPLY SIRONA in a research note on Monday, December 8th. They issued an “underweight” rating and a $12.00 price target on the stock. Finally, Wells Fargo & Company increased their price target on DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an “equal weight” rating in a report on Friday, February 27th.

Key Headlines Impacting DENTSPLY SIRONA

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: FDA clearance for a dental‑dedicated MRI (ddMRI) with Siemens Healthineers: this first‑of‑its‑kind imaging system expands XRAY’s advanced‑imaging addressable market and could drive higher‑margin equipment sales and recurring service revenue over time. First-ever Dental Dedicated MRI Validated…
• Positive Sentiment: Insider buying from directors (James Forbes and Gregory Lucier): recent purchases (~$12.45–$12.48/share) signal management/board confidence in the stock at current levels and can support sentiment if the buys continue. DENTSPLY SIRONA (NASDAQ:XRAY) Director James Forbes Buys 5,000 Shares
• Neutral Sentiment: Analysts are reworking valuation and risk assumptions: coverage shifts and updated models (discussed in a Yahoo Finance piece) are causing targets and ratings to be revisited — this fuels near‑term volatility but could clarify consensus levels over weeks. How The Dentsply Sirona (XRAY) Story Is Shifting…
• Neutral Sentiment: Presentation transcript from the Leerink Global Healthcare Conference: useful for incremental detail on strategy, margin actions and product cadence — may influence analyst revisions but no single headline takeaway. DENTSPLY SIRONA Presents at Leerink…
• Neutral Sentiment: Short‑interest reports show data anomalies (reported as 0 shares / 0 days to cover) — current disclosures appear unreliable, so there is no clear short‑squeeze or elevated short‑pressure signal from these entries. (Data point: average volume references included in filings.)
• Negative Sentiment: Recent quarterly results/earnings mix: revenue beat but an EPS miss and a negative net margin keep focus on profitability and leverage (market cap and leverage metrics remain notable). Analysts’ target adjustments are mixed (some cuts, some raises), leaving consensus at a “Hold” with average target ~$14.4 — downside remains if execution or margin recovery slows. DENTSPLY SIRONA (XRAY) MarketBeat summary

DENTSPLY SIRONA Price Performance

DENTSPLY SIRONA stock opened at $12.68 on Wednesday. The company has a current ratio of 1.51, a quick ratio of 1.03 and a debt-to-equity ratio of 1.50. The company has a 50-day moving average price of $12.69 and a 200 day moving average price of $12.43. DENTSPLY SIRONA has a 12-month low of $9.85 and a 12-month high of $17.18. The stock has a market cap of $2.53 billion, a P/E ratio of -4.23, a PEG ratio of 1.50 and a beta of 0.97.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The firm had revenue of $961.00 million during the quarter, compared to analyst estimates of $926.40 million. During the same quarter in the previous year, the firm earned $0.26 earnings per share. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Sell-side analysts anticipate that DENTSPLY SIRONA will post 1.84 earnings per share for the current year.

Insider Transactions at DENTSPLY SIRONA

In related news, Director James D. Forbes purchased 5,000 shares of DENTSPLY SIRONA stock in a transaction dated Monday, March 9th. The shares were acquired at an average cost of $12.48 per share, with a total value of $62,400.00. Following the purchase, the director owned 10,000 shares of the company’s stock, valued at approximately $124,800. The trade was a 100.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Gregory T. Lucier purchased 27,555 shares of DENTSPLY SIRONA stock in a transaction dated Monday, March 2nd. The stock was bought at an average cost of $14.24 per share, for a total transaction of $392,383.20. Following the completion of the purchase, the director directly owned 27,555 shares in the company, valued at approximately $392,383.20. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired 70,000 shares of company stock worth $956,437 in the last ninety days. 0.52% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On DENTSPLY SIRONA

A number of hedge funds have recently made changes to their positions in the stock. Daiwa Securities Group Inc. increased its holdings in DENTSPLY SIRONA by 2.9% in the 4th quarter. Daiwa Securities Group Inc. now owns 26,814 shares of the medical instruments supplier’s stock valued at $306,000 after purchasing an additional 767 shares during the last quarter. Arizona State Retirement System lifted its stake in DENTSPLY SIRONA by 1.4% during the third quarter. Arizona State Retirement System now owns 58,952 shares of the medical instruments supplier’s stock worth $748,000 after purchasing an additional 807 shares in the last quarter. True Wealth Design LLC lifted its stake in DENTSPLY SIRONA by 49.7% during the third quarter. True Wealth Design LLC now owns 3,557 shares of the medical instruments supplier’s stock worth $45,000 after purchasing an additional 1,181 shares in the last quarter. Sivia Capital Partners LLC boosted its position in shares of DENTSPLY SIRONA by 5.3% during the third quarter. Sivia Capital Partners LLC now owns 25,774 shares of the medical instruments supplier’s stock worth $327,000 after buying an additional 1,293 shares during the period. Finally, Empowered Funds LLC boosted its position in shares of DENTSPLY SIRONA by 8.8% during the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock worth $244,000 after buying an additional 1,320 shares during the period. Hedge funds and other institutional investors own 95.70% of the company’s stock.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.